Press Releases Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
1.4 ^USD	0.00%		+12.90%	+12.90%

Apr. 23	Averoa Seeks EU Approval for Chronic Kidney Disease Drug	MT
Apr. 16	Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights	May. 02	PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 01	PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	Apr. 03	AQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 02	PR
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis	Mar. 27	PR
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	Mar. 14	PR
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results	Mar. 11	PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	Mar. 04	AQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 01	PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 02	PR
Akebia Secures $55 Million Term Loan Financing	Jan. 30	PR
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer	Jan. 09	PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	Jan. 03	AQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 02	PR
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 20	PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	Dec. 04	AQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Dec. 01	PR
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference	Nov. 20	PR
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights	Nov. 09	AQ
Akebia Therapeutics: Q3 Earnings Snapshot	Nov. 08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Press Releases

Filters